NCT05734508View on ClinicalTrials.gov

Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC

PHASE4CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

March 23, 2023

Primary Completion Date

June 28, 2024

Study Completion Date

June 28, 2024

Conditions
Monkeypox
Interventions
BIOLOGICAL

MVA-BN vaccine

A live vaccine produced from the Modified Vaccinia Ankara-Bavarian Nordic strain (MVA-BN), an attenuated and non-replicating orthopox virus

Trial Locations (3)

Unknown

Institut National de Rescherche Biomédicale (INRB), Kinshasa

L'Hôpital Général de Référence de Kole, Kole

L'Hôpital Général de Référence de Tunda, Tunda

All Listed Sponsors
collaborator

Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH